ReviewCurrent opinion in HIV and AIDS2020
Long-acting injectable cabotegravir for the prevention of HIV infection.
Review in Current opinion in HIV and AIDS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.JMIR public health and surveillance · 2023Pooled it
- PrEP distribution in pharmacies: a systematic review.BMJ open · 2022Pooled it
- PrEPSteps: A Pilot Randomized Controlled Trial to Assess the Feasibility and Acceptability of a Digital Pill-Based PrEP Adherence Intervention in Men Who Have Sex with Men with Substance Use Disorder.AIDS and behavior · 2026Trial
- Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension.The lancet. HIV · 2024Trial
- Trial
- Testing the Effectiveness of a Motivational Interviewing Intervention to Reduce HIV Risk and Drug Use in Young Sexual Minority Men in a Community-Based Organization Setting.AIDS and behavior · 2024Trial
- Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention.The Journal of infectious diseases · 2022Trial
- Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).The Journal of antimicrobial chemotherapy · 2021Trial
- Trial
- Evaluating an Implementation Strategy Bundle in Title X-Funded Safety-Net Family Planning Clinics to Increase HIV Testing and PrEP Access Among Cis-Gender Women in Atlanta, United States: Lessons Learned From Provider Focus Groups.Journal of the International AIDS Society · 2026Article
- The Role of Healthcare-Related Experiences in Willingness and Preference for Long-Acting Injectable PrEP (LAI-PrEP) Among Transfeminine People in the United States.AIDS and behavior · 2026Article
- Preference for different PrEP formulations: A cross-sectional study in a PrEP cohort in Spain.HIV medicine · 2026Article
- Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness.Clinical microbiology reviews · 2026Review
- Alignment Between HIV Vulnerability and Pre-exposure Prophylaxis Use in a Longitudinal Study of Young, Black Men Who Have Sex with Men.AIDS and behavior · 2026Article
- Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir.Drugs in context · 2026Review
- Campus healthcare workers' knowledge and views on injectable pre-exposure prophylaxis prior to rollout in South Africa: A qualitative study.PLOS global public health · 2026Article
- Preferences for HIV preexposure prophylaxis care among gay, bisexual, and other MSM: a large discrete choice experiment.AIDS (London, England) · 2025Article
- PrEP Navigator Perceptions of the Implementation of Injectable PrEP on HIV Prevention in Tennessee.International journal of environmental research and public health · 2025Article
- Interactive effects of morphine and the HIV integrase inhibitor, cabotegravir, in male and female mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics.International journal of pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewThis review highlights the development of long-acting injectable cabotegravir (CAB LA) for HIV preexposure prophylaxis (PrEP), with a focus on phase 2 studies and later development. RECENT
findingsEarly studies of CAB LA for HIV prevention offered promising pharmacokinetic data and paved the way for phase 2 studies, which have now been completed. On the basis of phase 2 data, dosing of CAB LA at 8-week intervals consistently delivers target trough concentrations in both men and women. Recent studies have shown no required dose adjustments for hepatic or renal disease and minimal drug--drug interactions. Additionally, injectable PrEP is desired by potential PrEP candidates. Still, gaps in knowledge remain with respect to implementation and delivery, the clinical significance of the pharmacologic tail, and dosing in key populations. Phase 3 trials are underway that are anticipated to inform some of these questions and provide efficacy and safety data to support regulatory submissions for CAB LA as a potential PrEP agent. SUMMARY: Recent studies have defined an appropriate CAB LA dosing interval and offered insight into its safety profile. Phase 3 studies will provide much-anticipated efficacy data. If efficacious, CAB LA may provide a desirable PrEP option for those who face challenges to daily pill adherence. A more complete understanding of how to best integrate LA PrEP into service delivery models will be critical for success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.